Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00064636
Status:
TERMINATED
Last Update Posted:
2005-06-24
First Post:
2003-07-10
Brief Title:
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Study Overview
Official Title:
A Phase I Open Label Dose Escalation Study of PS-341 Plus Docetaxel in Treatment-Naive or Previously Treated Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Status:
TERMINATED
Status Verified Date:
2003-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate how safe VELCADE PS-341 is when given with Taxotere Docetaxel to patients with non-small cell lung cancer or other solid tumors and also to see what effects good and bad it has on you and your cancer
Detailed Description:
This is a dose escalation study which means that the first group of patients who enter the study will receive a low dose of VELCADE and Docetaxel If the low dose of VELCADE and Docetaxel appears to be safe then the next group of patients will receive a higher dose of VELCADE and docetaxel
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None